JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB217143

Anti-Delta Opioid Receptor antibody

Be the first to review this product! Submit a review

|

(1 Publication)

Rabbit Polyclonal Delta Opioid Receptor antibody. Suitable for WB and reacts with Mouse samples. Cited in 1 publication. Immunogen corresponding to Synthetic Peptide within Human OPRD1 aa 100-150 conjugated to Keyhole Limpet Haemocyanin.

View Alternative Names

OPRD, OPRD1, Delta-type opioid receptor, D-OR-1, DOR-1

1 Images
Western blot - Anti-Delta Opioid Receptor antibody (AB217143)
  • WB

Supplier Data

Western blot - Anti-Delta Opioid Receptor antibody (AB217143)

All lanes:

Western blot - Anti-Delta Opioid Receptor antibody (ab217143) at 1/300 dilution

All lanes:

Mouse heart lysates

Secondary

All lanes:

Goat Anti-Rabbit IgG Antibody (H+L), HRP Conjugated at 1/5000 dilution

Predicted band size: 40 kDa

false

Key facts

Host species

Rabbit

Clonality

Polyclonal

Isotype

IgG

Carrier free

No

Reacts with

Mouse

Applications

WB

applications

Immunogen

Synthetic Peptide within Human OPRD1 aa 100-150 conjugated to Keyhole Limpet Haemocyanin. The exact immunogen used to generate this antibody is proprietary information.

P41143

Specificity

ab217143 may also have a weak secondary cross-reaction with Mu-type opioid receptor, which is primarily expressed in the adrenal gland and testis. This is predicted based upon a 79% non-contiguous sequence similarity.

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Species", "Dilution Info", "Notes"], "tabs": { "all-applications": {"fullname" : "All Applications", "shortname": "All Applications"}, "WB" : {"fullname" : "Western blot", "shortname":"WB"} }, "product-promise": { "all": "all", "testedAndGuaranteed": "tested", "guaranteed": "expected", "predicted": "predicted", "notRecommended": "not-recommended" } }, "values": { "Human": { "WB-species-checked": "predicted", "WB-species-dilution-info": "", "WB-species-notes": "" }, "Mouse": { "WB-species-checked": "testedAndGuaranteed", "WB-species-dilution-info": "1/100 - 1/1000", "WB-species-notes": "<p></p>" }, "Rat": { "WB-species-checked": "predicted", "WB-species-dilution-info": "", "WB-species-notes": "" } } }

Properties and storage information

Form
Liquid
Purification technique
Affinity purification Protein A
Storage buffer
pH: 7.4 Preservative: 0.02% Proclin 300 Constituents: 50% Glycerol (glycerin, glycerine), 48.98% TBS, 1X, 1% BSA
Shipped at conditions
Blue Ice
Appropriate short-term storage duration
1-2 weeks
Appropriate short-term storage conditions
+4°C
Appropriate long-term storage conditions
-20°C
Aliquoting information
Upon delivery aliquot
Storage information
Avoid freeze / thaw cycle

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

The Delta Opioid Receptor also known as DOR is a G protein-coupled receptor involved in the modulation of pain mood and neuroprotection. It is a transmembrane protein with a mass around 40 kDa. The receptor is often expressed in the central nervous system particularly in areas such as the brain and spinal cord. Due to its role in analgesic pathways the receptor's function is of great interest for pain management therapies. Present in various tissues the presence of delta opioid receptors can influence different physiological processes.
Biological function summary

Delta opioid receptors participate in the modulation of neurotransmitter release neuronal excitability and neurogenesis. These receptors form part of a complex that includes other opioid receptors such as mu and kappa receptors interacting to fine-tune the body's response to pain and stress. Activation of delta opioid receptors results in analgesic effects making them potential targets for therapeutic interventions in pain management. Their expression in peripheral tissues also suggests roles in immune and inflammatory responses.

Pathways

Delta opioid receptors fit into the opioid receptor signaling cascades that influence pain perception and reward mechanisms. The major pathways include the adenylate cyclase inhibition pathway which reduces the production of cAMP and the MAPK cascade promoting cell survival and differentiation. These receptors commonly interact with G proteins such as Gi/o proteins to mediate cellular responses. Delta 5029 and delta 193 are segments of research focusing on specific pathways where delta 193 relates to receptor trafficking and delta 5029 involves receptor desensitization mechanisms.

Delta opioid receptors are linked to conditions like chronic pain and depression. Alterations in delta opioid receptor expression or function contribute to these disorders suggesting their involvement in pathological states. Through their involvement in opioid signaling they connect to disorders characterized by altered brain chemistry such as depression. Proteins interacting with delta receptors in these contexts include other opioid receptors which share overlapping roles in emotional regulation and pain perception. Antagonists or agonists like anti-delta antibodies are researched for potential therapeutic applications in these diseases.

Product protocols

For this product, it's our understanding that no specific protocols are required. You can visit:

Target data

G-protein coupled receptor that functions as a receptor for endogenous enkephalins and for a subset of other opioids. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Signaling leads to the inhibition of adenylate cyclase activity. Inhibits neurotransmitter release by reducing calcium ion currents and increasing potassium ion conductance. Plays a role in the perception of pain and in opiate-mediated analgesia. Plays a role in developing analgesic tolerance to morphine.
See full target information OPRD1

Publications (1)

Recent publications for all applications. Explore the full list and refine your search

Oxidative medicine and cellular longevity 2022:2262014 PubMed36439693

2022

A Prognostic Risk Model of a Novel Oxidative Stress-Related Signature Predicts Clinical Prognosis and Demonstrates Immune Relevancy in Lung Adenocarcinoma.

Applications

Unspecified application

Species

Unspecified reactive species

Xing Huang,Zhichao Lu,Min He,Yipeng Feng,Shaorong Yu,Bo Shen,Jianwei Lu,Pingping Wu,Banzhou Pan,Hanlin Ding,Chen Chen,Yidan Sun
View all publications

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com